GW Pharmaceuticals, PLC (GWPH)

gwpharma-logoGW Pharmaceuticals, PLC is a biopharmaceutical company based in United Kingdom, and is engaged in the research, manufacture, and commercialization of cannabinoid-based prescription medicines that contain controlled substances, and plant-based pharmaceutical products to meet the needs of patients in a range of therapeutic conditions. The company maintains in-house control over all aspects of the development process of their cannabinoid products, such as botanical research, extraction technology, drug formulation, clinical trials, and regulatory affairs.

Founded in 1998, GW Pharmaceuticals, PLC has become a world leader in cannabinoid science. The company has developed an international network of the field’s most prominent scientists. In 2007, the collaboration of GW and Otsuka paved the way for the significant expansion of the early cannabinoid research activities of GW. Both companies have collaborated in researching novel cannabinoids as potential treatments for central nervous system disorders. GW also has an in-house program that researches cannabinoids as treatments for Type 2 diabetes and related metabolic disorders.

The lead product of GW Pharmaceuticals, PLC is Sativex, which has been either approved for use or recommended for approval in 24 countries. Sativex is a treatment for symptom improvement in patients suffering from moderate to severe spasticity brought about by Multiple Sclerosis.

Sativex is currently in Phase III clinical development for cancer pain treatment. To provide patients from different countries with easy access to Sativex, the company has entered into separate licensing agreements with Almirall in Mexico and Europe; Bayer Healthcare in Canada and the UK; Otsuka Pharmaceutical in the U.S.; Novartis in Africa, Asia and the Middle East; and Neopharm in Israel.

GW Pharmaceuticals, PLC is listed under the symbol GWPH on the NASDAQ Global Market, as well as on AIM, a market of the London Stock Exchange. The company is licensed to work with controlled substances for medical research purposes. The company continues to focus on developing a product portfolio of cannabinoid-based prescription medicines, including Epidiolex and Sativex Oromucosal Spray, to meet the needs of patients in a wide range of medical indications.

Yahoo! Finance: GWPH News

Latest Financial News for GWPH

Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?

We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.

Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.

3 Top Healthcare Stocks to Buy in April

GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.

5 Marijuana Stocks Wall Street Is Most Bullish On

Cannabis and marijuana stocks are an exciting industry right now. According to Cowen & Co.'s Vivien Azer - a pioneer in cannabis-stock analysis - U.S. marijuana sales are set to reach about $80 billion by 2030. Currently, U.S. legal and illicit sales combined total at least $50 billion. That's on top of an estimated $C12 billion in Canadian revenue by 2025 for both recreational and medical use.The problem? It's still early days for the sector, which means significant risk is involved. It's common to see these primarily small- and mid-cap stocks move 10% or more in response to headlines or quarterly earnings reports. Companies are rushing to establish an early leadership position, and not all of them will end up winners. Plus, the federal legalization of cannabis in the U.S. remains a big question mark.So how do you pinpoint the most compelling investing opportunities in this lucrative industry? One option is to focus on the cannabis stocks that the Street is most bullish on right now.We used TipRanks market data to pinpoint five cannabis and marijuana stocks to buy based on overwhelmingly positive consensus ratings among Wall Street analysts. Let's take a closer look at each. SEE ALSO: Goldman Sachs: 7 Growth Stocks to Buy With Explosive Potential

How Cannabis Companies’ Upside Potential Stacks Up

Why Did Cannabis Stocks Fall on April 15?(Continued from Prior Part)Cannabis stocks Cannabis stocks were deep in the red on April 15. The sector is known for high volatility. Stocks in the cannabis space are more volatile compared to broader